Skip to main
ONC

BeiGene Ltd (ONC) Stock Forecast & Price Target

BeiGene Ltd (ONC) Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 38%
Buy 62%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

BeOne Medicines is a biotech company that is expected to continue its strong financial performance with ongoing trials and upcoming milestones. With a potential downside of 21% and an upside of 37%, the company's positive results for its currently approved drugs, Brukinsa and Sonrotoclax, suggest further success with its pipeline of over 50 drugs. There is some debate about the effectiveness of BeOne's unique approach to treating solid tumors, but their stock is currently valued at $430/ADR and analysts are recommending a Market Outperform rating.

Bears say

BeOne Medicines is a global commercial-stage biotech firm that produces oncology therapeutics. However, their main product, Brukinsa, has limited revenue potential outside of China and faces tough competition from established players like AbbVie and AstraZeneca. While they have a deep pipeline, the majority of their drugs are in early stages of development, posing a high level of risk for investors. Additionally, their recent phase 3 trial for SHINE showed mixed results and a high rate of adverse events, adding further uncertainty to the future success of their products. Hence, a negative outlook is warranted for BeOne Medicines' stock due to limited revenue potential, stiff competition, and high risk associated with their pipeline.

BeiGene Ltd (ONC) has been analyzed by 13 analysts, with a consensus rating of Buy. 38% of analysts recommend a Strong Buy, 62% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of BeiGene Ltd and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About BeiGene Ltd (ONC) Forecast

Analysts have given BeiGene Ltd (ONC) a Buy based on their latest research and market trends.

According to 13 analysts, BeiGene Ltd (ONC) has a Buy consensus rating as of Aug 13, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $404.92, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $404.92, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

BeiGene Ltd (ONC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.